PT - JOURNAL ARTICLE AU - Fink, Ashley L. AU - Liu, Hsuan AU - Shaw-Saliba, Kathryn AU - Mehoke, Thomas AU - Evans, Jared AU - Liu, Zhen-Ying AU - Lewis, Mitra AU - Sauer, Lauren AU - Thielen, Peter AU - Chen, Kuan-Fu AU - Rothman, Richard AU - Klein, Sabra L. AU - Pekosz, Andrew TI - Regional differences in vaccine uptake and serological responses to vaccine and circulating strains of H1N1 viruses among patients with confirmed influenza AID - 10.1101/2020.10.03.20203042 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.03.20203042 4099 - http://medrxiv.org/content/early/2020/10/06/2020.10.03.20203042.short 4100 - http://medrxiv.org/content/early/2020/10/06/2020.10.03.20203042.full AB - Background Seasonal epidemics of influenza are often characterized through national or international surveillance efforts to determine vaccine efficacy and vaccine strain selection, but they do not provide detailed information about local variations in factors that can influence influenza cases and disease severity.Methods Surveillance for influenza like illness was performed in Emergency Medicine Departments in Taipei, Taiwan and Baltimore, Maryland during the winter of 2015-16. Detailed demographic and clinical data were obtained. Nasal swabs or washes were collected for influenza virus diagnosis, sequencing and isolation. Serum was collected to determine neutralizing antibody levels.Results H1N1 viruses dominated both sites, but more influenza cases occurred in Taipei compared to Baltimore. H1 HA clade diversity was greater in Taipei. Vaccination rates were lower in Taipei than Baltimore, but vaccination was associated with an increase in serum neutralizing antibodies to recent H1N1 strains in Taipei, but not Baltimore. There was a higher level of preexisting immunity to circulating H1N1 strains in Baltimore.Conclusions Regional differences in preexisting immunity and H1N1 strain circulation may have contributed to the vastly different 2015-16 influenza seasons in Taipei and Baltimore and suggest immune responses to vaccination can be affected by the degree of preexisting immunity in the population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding This work was supported by the NIH/NIAID Center of Excellence in Influenza Research and Surveillance contract HHS N2772201400007C (R.R., K.F.C., and A.P.), T32 AI007417 (A.L.F.)the Richard Eliasberg Family Foundation and the Research Center for Emerging Viral Infections from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan and the Ministry of Science and Technology (MOST), Taiwan MOST 109-2634-F-182-001 (Y.N.G.). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The human subjects protocol was reviewed and approved by the JHMI Institutional Review Board (IRB) and the CGMH IRB (IRB00052743).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available for analysis by request.